Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic Malignancies


Jeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.

Jeffery Auletta, MD, physician, blood and marrow transplant (BMT), Hematology/Oncology/BMT, Infectious Diseases, Nationwide Children's Hospital; professor, pediatrics, The Ohio State University College of Medicine; member, the Leukemia Research Program, The Ohio State University Comprehensive Cancer Center; member, the Center for Regenerative Medicine and Cell-based Therapies, The Ohio State University, discusses the outcomes of comparing graft-versus-host disease (GVHD)–free, relapse-free survival (GRFS) and overall survival (OS) between 8/8 and 7/8 unrelated donor hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) in patients with acute leukemia or myelodysplastic syndromes (MDS).

PTCy has now become standard practice for preventing GVHD in both recipients of HLA-matched and -mismatched unrelated donor (URD) allografts, leading to successful HCT regardless of patient ancestry. The objective of this investigation was to discern disparities in OS and GRFS between 8/8 and 7/8 unrelated donor allografts when using PTCy compared with calcineurin-inhibitor (CNI)–based approaches, and to evaluate the impact of PTCy on remaining outcome differences due to HLA disparities.

Secondary objectives included comparing GRFS, OS, and other clinical outcomes among 8/8 and 7/8 URD recipients utilizing either PTCy- or CNI-based prophylaxis. The study involved adult patients undergoing initial URD HCT between January 2017 and June 2021.

The findings from this study demonstrate that using a mismatched URD yields similar outcomes to those observed when using a matched URD when employing PTCy as prophylaxis against GVHD, Auletta reports. Notably, although there was an outcome disparity in OS between 8/8 and 7/8 URD transplants with CNI-based GVHD prophylaxis, such a disparity was not observed when using PTCy, he explains.

Additionally, GRFS was comparable between 8/8 and 7/8 URD transplants with CNI-based GVHD prophylaxis but showed equivalence when using PTCy-based GVHD prophylaxis, with the latter demonstrating superior GRFS compared with URD transplants receiving CNI-based GVHD prophylaxis, Auletta concludes.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS